| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Kailera Therapeutics, Inc.$21.37
0 (0%)
C 48Pipeline Score Fair Value Biotech · Clinical
Market Cap
2.74 B
EPS
-
P/E Ratio
-
Value Trade
9.54 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
70.87 M
Operating CF
-68.31 M
Total Assets
624.76 M
Total Liabilities
64.48 M
Equity
-432.09 M
D/E Ratio
12,345
0.62 %
Week
-15.89 %
1 Month
-20.11 %
3 Month
-20.11 %
6 Month
-20.11 %
5 Year
-20.11 %
All Time
Cash Data
Cash Position
519.17 M
Monthly Burn
22.77 M
Runway
22 mo
Burn Trend
SEC Filing
May 26, 2026
Overview
Volume
473.95 K
52 Week Range
19.01 - 28.23
% held by Insiders
31.05 %
% held by Institutions
12.18 %
Enterprise Value
3.20 B
Total Shares
129.54 M
Short %
3.01 %
Float Shares
89.34 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C48
Pipeline Score $2.7B
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.0x
rNPV / MCap Top 73%
Small Cap (rank 245 of 905)
Percentile RankKailera Therapeutics, Inc. carries a moderate pipeline score (48/100), with $4.2B risk-adjusted pipeline value, led by KAI-9531 in Obesity (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KAI-9531 Small molecule | Obesity | Phase 3 | NCT07458269 | 58% | $3.2B | RECRUITING | 3,250 | VERY_FAST | B (74) | Jun 1, 2027 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KLRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
KLRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KLRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KLRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KLRA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
KLRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KLRAKailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Kailera Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4. CEO Ron Renaud will discuss the company's innovative pipeline focused on obesity care, including their lead candidate, ribupatide injection, currently in Phase 3 trials. The presentation will be available via live webcast and archived for 90 days.
Read more →KLRAKailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates • Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline • Initiat
Kailera Therapeutics has reported its first quarter 2026 financial results, highlighting important advances in its clinical pipeline targeting obesity. The company initiated five late-stage global trials, including the KaiNETIC Phase 3 program for ribupatide injection. Additionally, positive clinical data was reported from trials in collaboration with their partner Hengrui in China, showcasing the potential of various compounds in development. With sufficient cash reserves to fund operations until mid-2028, Kailera aims to maintain momentum in advancing its diverse portfolio of therapies.
Read more →KLRAKailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kailera Therapeutics has successfully closed its initial public offering, raising $718.8 million by offering 44,921,875 shares, including additional shares purchased by underwriters. The IPO was priced at $16.00 per share and is now listed on the Nasdaq under the ticker KLRA. The offering was managed by several prominent financial institutions.
Read more →KLRAKailera Therapeutics Announces Pricing of Initial Public Offering
Kailera Therapeutics has announced the pricing of its initial public offering, offering 39,062,500 shares at $16.00 each. The gross proceeds from this offering are projected to be $625 million, with trading set to begin on the Nasdaq under the ticker KLRA on April 17, 2026. The offering is expected to close on April 20, 2026, pending customary conditions.
Read more →Competitive Position
How KLRA ranks across every disease it competes inCompetitive Position is a premium feature
See how KLRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial